These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 22204093)

  • 21. Bevacizumab: serious neurological disorders and nasal perforations.
    Prescrire Int; 2007 Jun; 16(89):112. PubMed ID: 17582932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Side effects of gold salts].
    Renier JC; Boasson M
    Therapie; 1976; 31(3):365-76. PubMed ID: 136766
    [No Abstract]   [Full Text] [Related]  

  • 23. [Interstitial pneumonitis as a side effect of rituximab].
    Kemming JL; van Zeeland RE; Ullmann EF; Mattijssen EJ
    Ned Tijdschr Geneeskd; 2009; 153():A526. PubMed ID: 19785875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.
    Ostör AJ; Chilvers ER; Somerville MF; Lim AY; Lane SE; Crisp AJ; Scott DG
    J Rheumatol; 2006 Mar; 33(3):622-8. PubMed ID: 16511933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Third Tysabri adverse case hits drug class.
    Sheridan C
    Nat Rev Drug Discov; 2005 May; 4(5):357-8. PubMed ID: 15902765
    [No Abstract]   [Full Text] [Related]  

  • 26. Tysabri raises alarm bells on drug class.
    Sheridan C
    Nat Biotechnol; 2005 Apr; 23(4):397-8. PubMed ID: 15815649
    [No Abstract]   [Full Text] [Related]  

  • 27. [Prevention and treatment of complications caused by the use of antibiotics (literature survey)].
    Gostishchev VK; Tolstykh PI
    Vrach Delo; 1974; 0(7):13-8. PubMed ID: 4609356
    [No Abstract]   [Full Text] [Related]  

  • 28. Acute infusion reactions induced by monoclonal antibody therapy.
    Maggi E; Vultaggio A; Matucci A
    Expert Rev Clin Immunol; 2011 Jan; 7(1):55-63. PubMed ID: 21162650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Toxic effects of levamisole].
    Wen LY; Song CC
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2000; 18(3):186-7. PubMed ID: 12567708
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study.
    Gutin PH; Levi JA; Wiernik PH; Walker MD
    Cancer Treat Rep; 1977 Aug; 61(5):885-7. PubMed ID: 408003
    [No Abstract]   [Full Text] [Related]  

  • 31. [Adverse effects of antibiotics].
    Ono Y
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():224-31. PubMed ID: 18074543
    [No Abstract]   [Full Text] [Related]  

  • 32. Adverse effects resulting from nitrofurantoin administration.
    Delaney RA; Miller DA; Gerbino PP
    Am J Pharm Sci Support Public Health; 1977; 149(1):26-8. PubMed ID: 141888
    [No Abstract]   [Full Text] [Related]  

  • 33. [Adverse effects of cimetidine--the current situation].
    Alván G; Gustafsson LL; Ohman B
    Lakartidningen; 1979 Aug; 76(34):2767. PubMed ID: 529904
    [No Abstract]   [Full Text] [Related]  

  • 34. Monoclonal antibodies, immunogenicity, and associated infusion reactions.
    Cheifetz A; Mayer L
    Mt Sinai J Med; 2005 Jul; 72(4):250-6. PubMed ID: 16021319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [On iatrogenic damage caused by chemoantibiotic therapy of chronic bronchopneumopathies].
    Serra C
    Minerva Med; 1971 Feb; 62(16):770-5. PubMed ID: 4251442
    [No Abstract]   [Full Text] [Related]  

  • 36. Rituximab-induced interstitial lung disease: case report and literature review.
    Zayen A; Rais H; Rifi H; Ouarda M; Afrit M; Cherif A; Mezline A
    Pharmacology; 2011; 87(5-6):318-20. PubMed ID: 21613805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibody therapies and neurologic disorders.
    Novak JC; Lovett-Racke AE; Racke MK
    Arch Neurol; 2008 Sep; 65(9):1162-5. PubMed ID: 18779418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous granulomas during infliximab therapy for spondyloarthropathy.
    Dubosc AE; Perroud AM; Bagot M; Farenq V; Chevalier X; Maitre B; Claudepierre P
    J Rheumatol; 2008 Jun; 35(6):1222-3. PubMed ID: 18412298
    [No Abstract]   [Full Text] [Related]  

  • 39. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.
    Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM
    Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
    Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
    Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.